Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Nelutroctiv (CK-3828136) in Healthy Participants
NCT05662215Phase 1Terminated
- Sponsor
- Cytokinetics
- Start
- Dec 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nelutroctiv in heart failure with reduced ejection fraction (HFrEF) and right ventricular failure (RVF) (5 arms), sponsored by Cytokinetics. Primary endpoint: Incidence and severity of Adverse Events. Started Dec 2022; status: terminated.
02
Drugs
nelutroctiv
03
Conditions
heart failure with reduced ejection fraction (HFrEF)right ventricular failure (RVF)
Beyond the preview
Go deeper on NCT05662215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662215.